BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31874253)

  • 1. Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice.
    Beauchemin M; Geguchadze R; Guntur AR; Nevola K; Le PT; Barlow D; Rue M; Vary CPH; Lary CW; Motyl KJ; Houseknecht KL
    Pharmacol Res; 2020 Feb; 152():104589. PubMed ID: 31874253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice.
    Rostama B; Beauchemin M; Bouchard C; Bernier E; Vary CPH; May M; Houseknecht KL
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice.
    May M; Beauchemin M; Vary C; Barlow D; Houseknecht KL
    PLoS One; 2019; 14(6):e0218937. PubMed ID: 31242264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.
    Singh R; Bansal Y; Sodhi RK; Saroj P; Medhi B; Kuhad A
    Toxicol Appl Pharmacol; 2019 Sep; 378():114643. PubMed ID: 31254565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.
    Motyl KJ; Beauchemin M; Barlow D; Le PT; Nagano K; Treyball A; Contractor A; Baron R; Rosen CJ; Houseknecht KL
    Bone; 2017 Oct; 103():168-176. PubMed ID: 28689816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic antipsychotic treatment differentially modulates protein kinase A- and glycogen synthase kinase 3 beta-dependent signaling pathways, N-methyl-D-aspartate receptor and γ-aminobutyric acid A receptors in nucleus accumbens of juvenile rats.
    Pan B; Lian J; Deng C
    J Psychopharmacol; 2018 Nov; 32(11):1252-1263. PubMed ID: 30136620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice.
    Motyl KJ; DeMambro VE; Barlow D; Olshan D; Nagano K; Baron R; Rosen CJ; Houseknecht KL
    Endocrinology; 2015 Jul; 156(7):2374-83. PubMed ID: 25853667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.
    Li L; Yoo ES; Li X; Wyler SC; Chen X; Wan R; Arnold AG; Birnbaum SG; Jia L; Sohn JW; Liu C
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33978701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fos expression induced by olanzapine and risperidone in the central extended amygdala.
    Pinna A; Costa G; Contu L; Morelli M
    Eur J Pharmacol; 2019 Dec; 865():172764. PubMed ID: 31678081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.
    Ader M; Kim SP; Catalano KJ; Ionut V; Hucking K; Richey JM; Kabir M; Bergman RN
    Diabetes; 2005 Mar; 54(3):862-71. PubMed ID: 15734866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis.
    Mantere O; Trontti K; García-González J; Balcells I; Saarnio S; Mäntylä T; Lindgren M; Kieseppä T; Raij T; Honkanen JK; Vaarala O; Hovatta I; Suvisaari J
    J Psychiatr Res; 2019 Feb; 109():18-26. PubMed ID: 30463035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
    Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stathmin reduction and cytoskeleton rearrangement in rat nucleus accumbens in response to clozapine and risperidone treatment - Comparative proteomic study.
    Kedracka-Krok S; Swiderska B; Jankowska U; Skupien-Rabian B; Solich J; Dziedzicka-Wasylewska M
    Neuroscience; 2016 Mar; 316():63-81. PubMed ID: 26708747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.